Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Zogenix  (Stock symbol: ZGNX )

5858 Horton Street, Ste. 455
Emeryville, CA 94608
USA
858-259-1165
Website Company Summary Management Team
Management

CEO: Stephen J Farr (08/28/2006)
General Management: Bret Megargel (08/28/2006) ; Bradley Galer (12/31/2013) ; Joanne Quan (3/1/2020)
Finance: Michael P Smith (1/31/2017)
Technology: Eric Scharin (7/31/2018) ; Gail M Farfel (7/31/2015)
Business Development: Ashish Sagrolikar
General Counsel/Legal: Shawnte M Mitchell
Board

Outside board: (May no longer be on the board) Cam L Garner (Verus CEO) Curt C. Wheeler (Clarus Ventures General Partner);  Louis C Bock (Scale Venture Partners) James Breitmeyer (Cadence Pharmaceuticals Former EVP Development) Erie T Mast (Clovis Oncology Former CFO) Renee Tannenbaum (Halozyme VP Alliances) Mark Wiggins (Elcelyx Therapeutics Former EVP Business Development)
Former outside board: James C Blair (Domain Associates) Kurt C Wheeler (Clarus Ventures Managing Director) Roger L Hawley (Zogenix Former CEO) Alex Zisson (Thomas, McNerney & Partners Partner)
Former advisory board: Emmett Cunningham (Clarus Ventures Partner) Nimesh S Shah (Domain Associates Former Principal)
Company

Business description: Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The Company is preparing to resubmit its New Drug Application for FINTEPLA® (ZX008, fenfluramine) to the U.S. Food & Drug Administration for the treatment of seizures associated with Dravet syndrome, a rare and often-catastrophic infant-onset epilepsy that can include frequent and prolonged seizures and significant intellectual, behavioral, and motor disabilities. FINTEPLA® is under review by the European Medicines Agency and is in development in Japan, also for the treatment of Dravet syndrome, and is also in development globally for the treatment of Lennox-Gastaut syndrome, another severe childhood onset epilepsy.
Capital

Rounds: 3
Recent Fundings: Jul 2010   Jan 2008
Capital raised: 167.1M
Last Round: 15.0M
Ownership: Public   Ipo Filing
Stock Symbol: ZGNX
VCs include: Abingworth Management Scale Venture Partners Domain Associates ;  Thomas, McNerneyAndPartners Clarus Ventures ;  Chicago Growth Partners

Last Tweets


 

Last Mentions


Overview
Record updated: May 2020
Sector: Biotech
Headcount: 151-200 as of Aug 2019
Rounds: 3
Recent Fundings: Jul 2010   Jan 2008
Capital Raised: 167.1M
Last Round: 15.0M
Ownership: Public   Ipo Filing
Stock Symbol: ZGNX